Skip to main content

Advertisement

SpringerLink
Log in

Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor

  • Case Report- Pituitaries
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurrent BRAFV600E-mutated TTF-1-positive PPT treated with a BRAF inhibitor monotherapy (dabrafenib) leading to tumor regression. After 18 months of uninterrupted treatment, ongoing radiological tumor regression was observed and the patient remained asymptomatic without any significant adverse event. BRAF inhibitor is potentially a valuable treatment option for recurrent TTF-1-positive PPT with BRAF mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

PPT:

Posterior pituitary tumors

GTR:

Gross total resection

EETS:

Endoscopic transsphenoidal

SCO:

Spindle cell oncocytoma

PC:

Pituicytoma

NGS:

Next sequencing generation

GCT:

Granular cell tumor

References

  1. Das L, Vaiphei K, Rai A et al (2021) Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence. Endocr Connect 10(4):387–400. https://doi.org/10.1530/EC-20-0621

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Dawoud FM, Naylor RM, Giannini C, Swanson AA, Meyer FB, Uhm JH (2020) TTF-1 positive posterior pituitary tumor: limitations of current treatment and potential new hope in BRAF V600E mutation variants. Clin Neurol Neurosurg 196:106059. https://doi.org/10.1016/j.clineuro.2020.106059

    Article  PubMed  Google Scholar 

  3. Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y (2019) Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review. Cancers 11(12):1950. https://doi.org/10.3390/cancers11121950

    Article  CAS  PubMed Central  Google Scholar 

  4. Hasegawa H, Van Gompel JJ, Oushy SH et al (2021) A comprehensive study of spindle cell oncocytoma of the pituitary gland: series of 6 cases and meta-analysis of 85 cases. World Neurosurg 149:e197–e216. https://doi.org/10.1016/j.wneu.2021.02.051

    Article  PubMed  Google Scholar 

  5. Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535. https://doi.org/10.1007/s00401-017-1769-8

    Article  CAS  PubMed  Google Scholar 

  6. Maraka S, Janku F (2018) BRAF alterations in primary brain tumors. Discov Med 26(141):51–60

    PubMed  Google Scholar 

  7. Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243. https://doi.org/10.1097/PAS.0b013e31829723e7

    Article  CAS  Google Scholar 

  8. Mete O, Lopes MB, Asa SL (2013) Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 37(11):1694–1699. https://doi.org/10.1007/s12022-017-9498-z

    Article  CAS  PubMed  Google Scholar 

  9. Miller MB, Bi WL, Ramkissoon LA, et al (2016) MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget 7(24):37054–37063. https://doi.org/10.18632/oncotarget.9244

  10. Peuvrel L, Dréno B (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 15(5):425–444. https://doi.org/10.1007/s40257-014-0088-2

    Article  PubMed  Google Scholar 

  11. Roncaroli F, Chatterjee D, Giannini C et al (2020) Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF-1-positive sellar lesions. Neuropathol Appl Neurobiol 46(5):493–505. https://doi.org/10.1111/nan.12622

    Article  CAS  PubMed  Google Scholar 

  12. Salge-Arrieta FJ, Carrasco-Moro R, Rodríguez-Berrocal V, Pian H, Martínez-San Millán JS, Iglesias P, Ley-Urzáiz L (2019) Clinical features, diagnosis and therapy of pituicytoma: an update. J Endocrinol Invest 42(4):371–384. https://doi.org/10.1007/s40618-018-0923-z

    Article  CAS  PubMed  Google Scholar 

  13. Sollfrank L, Lettmaier S, Erdmann M, Uslu U (2019) Panniculitis under successful targeted inhibition of the MAPK/ERK signaling pathway in a patient with BRAF V600E-mutated spindle cell oncocytoma of the pituitary gland. Anticancer Res 39(7):3955–3959. https://doi.org/10.21873/anticanres.13549

  14. Viaene AN, Lee EB, Rosenbaum JN, Nasrallah IM, Nasrallah MP (2019) Histologic, immunohistochemical, and molecular features of pituicytomas and atypical pituicytomas. Acta Neuropathol Commun 7(1):69. https://doi.org/10.1186/s40478-019-0722-6

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Erasme Hospital, ULB, Route de Lennik, 808, 1070, Anderlecht, Belgium

    Flavie Grenier-Chartrand, Sami Barrit, Julien Spitaels, Florence Lefranc & Olivier De Witte

  2. Department of Pathology, Erasme Hospital, ULB, Anderlecht, Belgium

    Marie Lucie Racu, Laetitia Lebrun & Isabelle Salmon

  3. Department of Oncology, Erasme Hospital, ULB, Anderlecht, Belgium

    Sylvie Luce

  4. Department of Neuro-Radiology, Erasme Hospital, ULB, Anderlecht, Belgium

    Niloufar Sadeghi-Meibodi

Authors
  1. Flavie Grenier-Chartrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sami Barrit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie Lucie Racu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvie Luce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julien Spitaels
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Niloufar Sadeghi-Meibodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laetitia Lebrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Isabelle Salmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Florence Lefranc
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Olivier De Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Flavie Grenier-Chartrand.

Ethics declarations

Consent to publish

The patient has consented to the submission of the case report to the journal.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pituitaries

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grenier-Chartrand, F., Barrit, S., Racu, M.L. et al. Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor. Acta Neurochir 164, 737–742 (2022). https://doi.org/10.1007/s00701-022-05109-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-022-05109-w

Keywords

Search

Navigation